Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
University of California, San Francisco
National Institutes of Health Clinical Center (CC)
Servier
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
The First Affiliated Hospital of Xiamen University
M.D. Anderson Cancer Center
Stanford University
University of Maryland, Baltimore
M.D. Anderson Cancer Center
Eli Lilly and Company
M.D. Anderson Cancer Center
Children's Hospital of Philadelphia
Instituto do Cancer do Estado de São Paulo
Radboud University Medical Center
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Providence Health & Services
Zhejiang Cancer Hospital
Turning Point Therapeutics, Inc.
Eastern Cooperative Oncology Group
M.D. Anderson Cancer Center
Sotio Biotech Inc.
Pfizer
Pfizer
Memorial Sloan Kettering Cancer Center
Dartmouth-Hitchcock Medical Center
Shahida Islam Medical Complex
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Stanford University
Washington University School of Medicine
University of Chicago
Grupo Espanol de Tumores Neuroendocrinos
FindCure Biosciences (ZhongShan) Co., Ltd.
Gustave Roussy, Cancer Campus, Grand Paris
Eisai Inc.
Università Cattolica di Milano
Erasca, Inc.
Fudan University
Fudan University
Fudan University
Ankara University
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Kaiser Permanente